ATE444082T1 - Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür - Google Patents

Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür

Info

Publication number
ATE444082T1
ATE444082T1 AT01978210T AT01978210T ATE444082T1 AT E444082 T1 ATE444082 T1 AT E444082T1 AT 01978210 T AT01978210 T AT 01978210T AT 01978210 T AT01978210 T AT 01978210T AT E444082 T1 ATE444082 T1 AT E444082T1
Authority
AT
Austria
Prior art keywords
haptoglobin
function
receptor
hemoglobin receptor
complex
Prior art date
Application number
AT01978210T
Other languages
English (en)
Inventor
Soren Moestrup
Holger Moller
Original Assignee
Cytoguide Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoguide Aps filed Critical Cytoguide Aps
Application granted granted Critical
Publication of ATE444082T1 publication Critical patent/ATE444082T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01978210T 2000-10-16 2001-10-12 Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür ATE444082T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200001543 2000-10-16
DKPA200100039 2001-01-11
US27012001P 2001-02-22 2001-02-22
PCT/DK2001/000671 WO2002032941A2 (en) 2000-10-16 2001-10-12 The function of a haptoglobin-haemoglobin receptor and the uses thereof

Publications (1)

Publication Number Publication Date
ATE444082T1 true ATE444082T1 (de) 2009-10-15

Family

ID=27222446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01978210T ATE444082T1 (de) 2000-10-16 2001-10-12 Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür

Country Status (10)

Country Link
US (3) US20020155995A1 (de)
EP (1) EP1328297B1 (de)
AT (1) ATE444082T1 (de)
AU (1) AU2002210383A1 (de)
CY (1) CY1110579T1 (de)
DE (1) DE60140069D1 (de)
DK (1) DK1328297T3 (de)
ES (1) ES2334103T3 (de)
PT (1) PT1328297E (de)
WO (1) WO2002032941A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1328297B1 (de) 2000-10-16 2009-09-30 Cytoguide ApS Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
EP1372716B1 (de) * 2001-03-26 2009-01-28 Therapure Biopharma Inc. Produktion von blutzellen mittels aktivierung von cd163
EP1367393A1 (de) * 2002-05-27 2003-12-03 MacroZyme B.V. Verfahren zur Verwendung des CD 163 Wegs zur Modulation einer Immunantwort
WO2003100419A1 (en) * 2002-05-27 2003-12-04 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2008019186A2 (en) * 2006-05-26 2008-02-14 Temple University - Of The Commonwealth System Of Higher Education Blood monocyte cd163 expression as a biomarker in hiv-1 infection and neuroaids
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
EP2488863A2 (de) 2009-10-12 2012-08-22 Aarhus Universitet Prognoseverfahren
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
CN110256571A (zh) * 2018-11-30 2019-09-20 莱尔芙高新技术(上海)有限公司 重组人白蛋白-血红蛋白β亚基融合蛋白
WO2020236952A1 (en) * 2019-05-20 2020-11-26 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
AU2020315878A1 (en) 2019-07-19 2022-03-03 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
KR102254246B1 (ko) * 2020-03-23 2021-05-20 큐벳 주식회사 항-cd163 항체 또는 이의 항원 결합 단편을 인코딩하는 핵산 분자 및 이를 포함하는 아데노바이러스 벡터, 및 이의 아프리카 돼지열병의 예방 또는 치료용도
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
KR20230074775A (ko) 2020-09-23 2023-05-31 아블레비아 바이오테크 게엠베하 바이러스 벡터의 효능 증가를 위한 화합물
CN116669755A (zh) 2020-09-23 2023-08-29 艾柏力维亚生技有限公司 用于增加因子viii替代疗法的效力的化合物
CN116635081A (zh) 2020-09-23 2023-08-22 艾柏力维亚生技有限公司 用于预防或治疗自身抗体-介导的疾病的化合物
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US20230381328A1 (en) 2020-09-24 2023-11-30 Ablevia Biotech Gmbh Compound for the prevention or treatment of myasthenia gravis
US20240053363A1 (en) * 2021-01-05 2024-02-15 Public University Corporation Yokohama City University Biomarker for determining fertility, and determining method using same
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US41177A (en) * 1864-01-05 Tiios
US4177A (en) * 1845-09-02 Phineas bennet
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5252348A (en) 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
EP0769063A1 (de) 1994-06-27 1997-04-23 The Johns Hopkins University Gezielte freigabe genetischen materials
US5691197A (en) 1995-02-21 1997-11-25 Tryggvason; Karl Isolated DNA sequence for a novel macrophage receptor with a collagenous domain
AU711702B2 (en) 1995-03-23 1999-10-21 Cambridge University Technical Services Limited Vectors for gene delivery
JPH11512451A (ja) * 1995-09-21 1999-10-26 アンダリス、リミテッド 薬剤送達のためのトランスサイトーシスビヒクルおよびエンハンサー
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6046314A (en) 1997-03-06 2000-04-04 Bristol-Myers Squibb Co. Spα: a novel scavenger receptor cysteine-rich domain-containing polypeptide, and monoclonal antibodies thereto
US5962667A (en) 1997-11-03 1999-10-05 Virginia Commonwealth University Pharmaco-gene delivery in human breast cancer cells
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
ES2287115T3 (es) * 2000-03-28 2007-12-16 Trustees Of Dartmouth College Procedimiento para la deteccion de una inflamacion y de estados inflamatorios.
EP1328297B1 (de) 2000-10-16 2009-09-30 Cytoguide ApS Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods

Also Published As

Publication number Publication date
PT1328297E (pt) 2010-01-04
WO2002032941A3 (en) 2002-07-25
EP1328297B1 (de) 2009-09-30
DE60140069D1 (de) 2009-11-12
WO2002032941A2 (en) 2002-04-25
US20080242843A1 (en) 2008-10-02
CY1110579T1 (el) 2015-04-29
US9476890B2 (en) 2016-10-25
AU2002210383A1 (en) 2002-04-29
US20050063951A1 (en) 2005-03-24
EP1328297A2 (de) 2003-07-23
DK1328297T3 (da) 2010-02-01
ES2334103T3 (es) 2010-03-05
WO2002032941A8 (en) 2004-04-29
US20020155995A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
ATE444082T1 (de) Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
DE59906975D1 (de) Wässrige reaktive spachtelmassen (i)
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
DK1124568T3 (da) Polyspecifikke bindingsmolekyler og anvendelser deraf
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
WO2008073162A3 (en) Lysine acetylation sites
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
SE0102327D0 (sv) A novel engineered superantigen for human therapy
NZ331189A (en) Method of detection of influenza virus using neuraminidase binders
TW200612945A (en) Aerosol suspension formulations containing TG 227 ea as propellant
EA200702193A1 (ru) Гликозилирование белков
EP1983002A3 (de) Tyrosinphosphorylations-Stellen und spezifische Antikörper
DK1216707T3 (da) Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet
WO2008054597A3 (en) Tyrosine phosphorylation sites
WO2008013954A3 (en) Tyrosine phosphorylation sites
NO20021686D0 (no) Fremgangsmåter for fremstilling av målemolekyler i et transgent dyr og rensing av målmolekylet
NO20062410L (no) Malretting av ERB-antigener
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
WO2008013934A3 (en) Tyrosine phosphorylation sites
NO20074805L (no) Fremgangsmate for a identifisere PDE11-modulatorer
WO2008113916A9 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w
WO2002020563A3 (de) REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328297

Country of ref document: EP